Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
175
-
Total 13F shares, excl. options
-
38.4M
-
Shares change
-
-5.05M
-
Total reported value, excl. options
-
$879M
-
Value change
-
-$113M
-
Put/Call ratio
-
0.65
-
Number of buys
-
96
-
Number of sells
-
-76
-
Price
-
$22.87
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q4 2021
245 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q4 2021.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 175 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.4M shares
of 131M outstanding shares and own 29.39% of the company stock.
Largest 10 shareholders include FMR LLC (5.73M shares), MORGAN STANLEY (4.75M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (3.39M shares), NEA Management Company, LLC (3.07M shares), BlackRock Inc. (1.82M shares), PICTET ASSET MANAGEMENT SA (1.45M shares), Artal Group S.A. (1M shares), Melqart Asset Management (UK) Ltd (916K shares), VOLORIDGE INVESTMENT MANAGEMENT, LLC (881K shares), and CITIGROUP INC (768K shares).
This table shows the top 175 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.